Literature DB >> 10966268

Nitric oxide synthase inhibition increases venular leukocyte rolling and adhesion in septic rats.

R Sundrani1, C R Easington, A Mattoo, J E Parrillo, S M Hollenberg.   

Abstract

OBJECTIVE: Excess production of nitric oxide (NO) has been implicated in hypotension and blood flow abnormalities in sepsis, but NO is also an important inhibitor of leukocyte rolling and adhesion. Leukocyte adhesion is increased in sepsis despite elevated NO production. We hypothesized that inhibition of NO synthase (NOS) could increase leukocyte adhesion in sepsis.
DESIGN: Prospective animal study.
SETTING: Experimental animal laboratory.
SUBJECTS: Twenty-five male rats, anesthetized with ketamine and acepromazine.
INTERVENTIONS: Topical superfusion of the nonselective NOS inhibitor N(G)-monomethyl-L-arginine (NMA) on skeletal muscle postcapillary venules.
MEASUREMENTS AND MAIN RESULTS: Rats made septic by cecal ligation and puncture were compared with controls that underwent sham ligation. Leukocyte rolling and adhesion were measured in cremasteric postcapillary venules of septic and control rats using in vivo videomicroscopy. The effects of NOS inhibition on leukocyte rolling and adhesion were also measured. After a stable baseline was reached, 1 microM of the nonselective NOS inhibitor NMA was suffused topically followed by physiologic buffer. The effects of L-arginine on leukocyte rolling and adhesion were also measured, both before and after suffusion of NMA. Leukocyte rolling and adhesion was increased in septic rats as compared with controls (control 5.5+/-0.9 rolling cells/min, 1.0+/-0.3 adherent cells/min; septic 13.7+/-2.0 rolling cells/min, 3.1+/-0.6 adherent cells/min; p < .001), and NOS inhibition further increased leukocyte rolling and adhesion in both septic and control rats (control 14.0+/-1.7 rolling cells/min, 2.8+/-0.5 adherent cells/min; septic 25+/-2.1 rolling cells/min, 5.4+/-0.5 adherent cells/min; both p < .001 vs. baseline). Prior suffusion of excess L-arginine prevented the increase in leukocyte adhesion with NMA in septic rats (2.6+/-0.4 adherent cells/min vs. 3.0+/-0.6 adherent cells/min; n = 3; p > .05). When administered after NMA, excess L-arginine partially reversed leukocyte adhesion in septic rats (5.4+/-0.7 adherent cells/min, with NMA vs. 4.3+/-0.7 adherent cells/min, after L-arginine; n = 5; p < .05). Venular shear did not differ between septic and control rats (600+/-109 (sec(-1)) vs. 620+/-37 (sec(-1)); p > .05).
CONCLUSIONS: Although NOS inhibition may ameliorate hypotension in sepsis, such therapy may be deleterious by increasing leukocyte adhesion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10966268     DOI: 10.1097/00003246-200008000-00035

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  5 in total

Review 1.  Bench-to-bedside review: nitric oxide in critical illness--update 2008.

Authors:  Steven M Hollenberg; Ismail Cinel
Journal:  Crit Care       Date:  2009-07-16       Impact factor: 9.097

Review 2.  Resuscitating the microcirculation in sepsis: the central role of nitric oxide, emerging concepts for novel therapies, and challenges for clinical trials.

Authors:  Stephen Trzeciak; Ismail Cinel; R Phillip Dellinger; Nathan I Shapiro; Ryan C Arnold; Joseph E Parrillo; Steven M Hollenberg
Journal:  Acad Emerg Med       Date:  2008-05       Impact factor: 3.451

3.  Nitric oxide and TNFα are critical regulators of reversible lymph node vascular remodeling and adaptive immune response.

Authors:  Stephanie L Sellers; Akiko Iwasaki; Geoffrey W Payne
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

4.  Discordance between microvascular permeability and leukocyte dynamics in septic inducible nitric oxide synthase deficient mice.

Authors:  Steven M Hollenberg; Massimiliano Guglielmi; Joseph E Parrillo
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

5.  Nitric oxide, leukocytes and microvascular permeability: causality or bystanders?

Authors:  Balázs Hauser; Martin Matejovic; Peter Radermacher
Journal:  Crit Care       Date:  2008-01-16       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.